Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS

Crinetics Pharmaceuticals (NASDAQ:CRNX) announced its quarterly earnings results on Thursday. The company reported ($1.29) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.08, FiscalAI reports. Crinetics Pharmaceuticals’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.88) EPS.

Here are the key takeaways from Crinetics Pharmaceuticals’ conference call:

• Crinetics reported initial commercial traction for PALSONIFY with $5.4M in Q4 product revenue, >125 unique prescribers, >200 enrollment forms, and a positive CHMP opinion in the EU supporting broader market expansion.
• Atumelnant showed rapid, large cortisol declines and good tolerability in NIH proof-of-concept data, and the seamless EQUILIBRIUM Phase 2/3 study for ACTH-dependent Cushing’s syndrome has been initiated (H1 2026) to confirm dose, glucocorticoid-replacement strategy, and pivotal efficacy.
• The novel nonpeptide drug conjugate CRN09682 has entered dose escalation in a Phase 1/2 basket study (BRAVESST2) for SST2‑expressing tumors, offering broad potential but remaining early-stage and high uncertainty on clinical benefit size and timing.
• Financially the company ended 2025 with >$1B in cash and investments and received ~$380M net in Jan 2026 equity proceeds (pro forma ~ $1.4B), giving a stated runway into 2030 to fund launches and multiple pivotal readouts.
• Market access momentum is encouraging—Crinetics reports formulary wins with straightforward prior authorizations and about half of initial patients reimbursed while a QuickStart program bridges others, with the company expecting QuickStart use to decline as coverage expands.

Crinetics Pharmaceuticals Trading Up 0.8%

CRNX stock traded up $0.35 during midday trading on Thursday, reaching $43.74. 824,737 shares of the company’s stock traded hands, compared to its average volume of 1,294,001. Crinetics Pharmaceuticals has a 52-week low of $24.10 and a 52-week high of $57.99. The stock has a market cap of $4.47 billion, a P/E ratio of -9.66 and a beta of 0.19. The stock’s 50-day moving average is $49.00 and its 200 day moving average is $43.01.

Insider Activity at Crinetics Pharmaceuticals

In other news, insider Isabel Kalofonos sold 2,500 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the transaction, the insider directly owned 834 shares of the company’s stock, valued at $45,870. The trade was a 74.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CRNX. Smartleaf Asset Management LLC increased its stake in shares of Crinetics Pharmaceuticals by 107.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock worth $30,000 after purchasing an additional 331 shares in the last quarter. Headlands Technologies LLC bought a new position in Crinetics Pharmaceuticals in the 2nd quarter worth $30,000. Parallel Advisors LLC increased its stake in Crinetics Pharmaceuticals by 34.6% in the 4th quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock worth $57,000 after buying an additional 315 shares in the last quarter. Arax Advisory Partners increased its stake in Crinetics Pharmaceuticals by 131.2% in the 4th quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock worth $70,000 after buying an additional 850 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Crinetics Pharmaceuticals during the second quarter valued at about $45,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Wall Street Analyst Weigh In

CRNX has been the subject of a number of research analyst reports. Citizens Jmp reduced their target price on Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating for the company in a report on Thursday, January 8th. Morgan Stanley lifted their price objective on Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 target price on the stock in a research note on Monday, January 12th. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $75.78.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.